Primecap Management Co. CA Trims Stock Position in BioNTech SE (NASDAQ:BNTX)

Primecap Management Co. CA trimmed its holdings in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 4.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,295,817 shares of the company's stock after selling 220,701 shares during the period. Primecap Management Co. CA owned about 1.79% of BioNTech worth $489,508,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in BNTX. Midwest Professional Planners LTD. boosted its stake in BioNTech by 5.8% in the fourth quarter. Midwest Professional Planners LTD. now owns 4,051 shares of the company's stock valued at $462,000 after acquiring an additional 222 shares during the last quarter. LBP AM SA raised its holdings in shares of BioNTech by 2.1% in the 4th quarter. LBP AM SA now owns 252,918 shares of the company's stock worth $28,820,000 after purchasing an additional 5,085 shares during the period. Vestcor Inc lifted its stake in BioNTech by 50.0% in the fourth quarter. Vestcor Inc now owns 9,900 shares of the company's stock valued at $1,128,000 after purchasing an additional 3,300 shares during the last quarter. Daiwa Securities Group Inc. grew its holdings in BioNTech by 7.1% during the fourth quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company's stock valued at $221,000 after purchasing an additional 128 shares during the period. Finally, Generali Investments CEE investicni spolecnost a.s. purchased a new stake in BioNTech in the fourth quarter worth $137,000. Institutional investors own 15.52% of the company's stock.

BioNTech Price Performance

NASDAQ:BNTX traded down $0.85 during midday trading on Friday, hitting $95.38. The company had a trading volume of 787,017 shares, compared to its average volume of 785,020. The company has a market capitalization of $22.89 billion, a PE ratio of -45.42 and a beta of 0.30. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. BioNTech SE has a 52-week low of $76.53 and a 52-week high of $131.49. The stock's fifty day moving average price is $113.57 and its 200-day moving average price is $113.32.

Remove Ads

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.38 by $0.70. The firm had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company's revenue for the quarter was down 19.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.90 earnings per share. As a group, research analysts expect that BioNTech SE will post -3.88 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Wells Fargo & Company assumed coverage on BioNTech in a research note on Wednesday, December 11th. They set an "overweight" rating and a $170.00 price target for the company. Morgan Stanley lowered their price target on shares of BioNTech from $145.00 to $139.00 and set an "overweight" rating on the stock in a research report on Tuesday, March 11th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $171.44 price objective on shares of BioNTech in a report on Tuesday, March 11th. Truist Financial initiated coverage on shares of BioNTech in a report on Friday, January 10th. They set a "buy" rating and a $172.00 target price on the stock. Finally, BMO Capital Markets raised their price target on BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a report on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $143.73.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.